Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: A retrospective survey

Blood

Volumn 111, Issue 2, 2008, Pages 666-671

  Ruggeri, Marco ^a   Rodeghiero, Francesco ^a   Tosetto, Alberto ^a   Castaman, Giancarlo ^a   Scognamiglio, Francesca ^a   Finazzi, Guido ^b   Delaini, Federica ^b   Micò, Caterina ^b   Vannucchi, Alessandro M ^c   Antonioli, Elisabetta ^c   De Stefano, Valerio ^d   Za, Tommaso ^d   Gugliotta, Luigi ^e   Tieghi, Alessia ^e   Mazzucconi, Maria Gabriella ^f   Santoro, Cristina ^f   Barbui, Tiziano ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b OSPEDALI RIUNITI   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; ARTERY THROMBOSIS; ARTICLE; BLEEDING; BLOOD VESSEL OCCLUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; EMERGENCY SURGERY; FEMALE; FOLLOW UP; GENERAL ANESTHESIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THROMBOSIS; THROMBOSIS PREVENTION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 38349175356     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-102665     Document Type: Article

References (36)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-375.
2. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755-761.
3. Rozman C, Giralt M, Feliu E, Rubio D, Cortes MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer. 1991;67:2658-2663.
4. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long term complications rates, and prognostic factors. Mayo Clin Proc. 2006;81:159-166.
5. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia. Ann Inter Med. 1995;123:656-664.
6. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556-562.
7. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol. 2004;128:275-290.
8. Harrison CN. Essential thrombocytemia: challenges and evidence-based management. Br J Haematol. 2005;130:153-165.
9. Tefferi A, Mesa RA, Nagorney DM, Schroeder G, Silverstein MN. Splenectomy in myelofibrosis with myeloid metaplasia: a single institution experience with 223 patients. Blood. 2000;95:2226-2233.
10. Randi ML, Luzzato G, Ruzzon E, Pacquola E, Cella G, Girolami A. Splenectomy after portal thrombosis in patients with polycythemia vera and essential thrombocythemia. Haematologica. 2002;87:1180-1184.
11. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004;89:215-232.
12. Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339-351.
13. Pearson TC, Messinezy M. The diagnostic criteria of polycythemia rubra vera. Leuk Lymphoma. 1996;22:87-93.
14. Murphy S, Iland H, Rosenthal D, et al. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin Hematol. 1986;23:177-182.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haemopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
16. Landolfi R, Marchioli R, Kutti J, et al, for the European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114-124.
17. Palareti G, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet. 1996;348:423-428.
18. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, version 3.0. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
19. Barbui T, Finazzi G. Myeloproliferative disease in pregnancy and other management issues. Hematology. 2006;246-252.
20. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224-2232.
21. Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446-2452.
22. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood. 2007;109:2310-2313.
23. Michiels JJ, Berneman ZN, Schroyens W. Pathophysiology and treatment of platelet-mediated microvascular disturbance, major thrombosis and bleeding complications in essential thrombocythaemia and polycythaemia vera. Platelets. 2004;15:67-84.
24. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest. 2004;126(suppl):338S-400S.
25. Leonardi MJ, McGory ML, Ko CY. A systematic review of deep vein thrombosis prophylaxis in cancer patients: implications for improving quality. Ann Surg Oncol. Now available as Ann Surg Oncol. 2007;14:929-936.
26. Lee AYY. Management of thrombosis in cancer: primary prevention and secondary prophylaxis. Br J Haematol. 2005;128:291-302.
27. Kosir MA, Schittinger L, Barno-Winarski, et al. Prospective double arm study of fibrinolysis in surgical patients. J Surg Res. 1998;74:96-101.
28. Valle I, Sola G, Origone A. Controlled clinical study of the efficacy of a new low molecular weight heparin administered subcutaneously to prevent post-operative deep vein thrombosis. Curr Med Res Opin. 1988;11:80-86.
29. Eriksson BI, Bauer KA, Lassen MR, Turpie AG for the Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med. 2001;355:1298-1303.
30. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythemia vera. Nature. 2005;434:1144-1148.
31. BaxterEJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 I human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
32. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
33. Antonioli E, Guglielmelli P, Pancrazzi A, et al. Clinical implication of the JAK2 V617F mutation in essential thrombocythemia. Leukemia. 2005;19:1847-1849.
34. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK 2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208-213.
35. Vannucchi AM, Antonioli E. Guglielmelli P, et al. Clinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia Blood. 2007;110:840-846.
36. Tefferi A, Elliott MA. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors and role of leukocytes and JAK2V617F. Semin Thromb Hemost. 2007;33:313-320.